Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2014 Feb 23;9(3):388–398. doi: 10.1007/s11481-014-9529-1

Fig. 5.

Fig. 5

ADP355 preserves cognitive performance in PI-treated mice. Male C57BL/6 mice were treated daily with vehicle or lopinavir/ritonavir (150/37.5 mg/kg body weight) for 28 days, after which mice were evaluated behaviorally for memory performance using the fear conditioning assay as described in Methods. Experiments were conducted in 12–20 animals per group over 2 separate cohorts. Data are means ± S.E.M. of composite freezing behavior, and were analyzed by 2-way ANOVA. *and *** indicate significant (p<0.05, p<0.001, respectively) decreases in freezing behavior in lopinavir/ritonavir/PBS-treated mice as compared to vehicle-treated mice, while # and ### depict significant (p<0.05, p<0.001, respectively) increases in freezing in lopinavir/ritonavir-treated mice given ADP355 as compared to lopinavir/ritonavir-treated given PBS